These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 32513535)
41. Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence. Marseglia GL; Gelardi M; Santus P; Ciprandi G Minerva Med; 2024 Aug; 115(4):503-515. PubMed ID: 39016527 [TBL] [Abstract][Full Text] [Related]
42. [Pidotimod causes apoptotic cell death and inhibits the proliferative activity of YAC-1 tumor cells in vitro]. Migliorati G; Nicoletti I; Delfino D; Maggioni A; Coppi G; Riccardi C Drugs Exp Clin Res; 1993; 19 Suppl():1-7. PubMed ID: 8625777 [No Abstract] [Full Text] [Related]
43. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791 [TBL] [Abstract][Full Text] [Related]
44. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. Zhang M; Yin T; Lu Y; Feng H Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689 [TBL] [Abstract][Full Text] [Related]
45. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Aivazis V; Hatzimichail A; Papachristou A; Valeri R; Iuga-Donca G Minerva Pediatr; 2002 Aug; 54(4):315-9. PubMed ID: 12131867 [TBL] [Abstract][Full Text] [Related]
46. [Pidotimod, a new biological response modifier, is able to partially prevent immune response changes related to surgical stress]. Pasqui AL; Bruni F; Di Renzo M; Saletti M; Bova G; Gotti G; Auteri A Drugs Exp Clin Res; 1993; 19 Suppl():45-53. PubMed ID: 8625782 [No Abstract] [Full Text] [Related]
47. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Taramelli D; Malabarba MG; Basilico N; Sala G; Mattina R; Cocuzza C Arzneimittelforschung; 1994 Dec; 44(12A):1425-30. PubMed ID: 7857336 [TBL] [Abstract][Full Text] [Related]
48. The regulatory peptide pidotimod facilitates M2 macrophage polarization and its function. Hu S; Fu X; Fu A; Du W; Ji J; Li W Amino Acids; 2014 May; 46(5):1177-85. PubMed ID: 24481486 [TBL] [Abstract][Full Text] [Related]
49. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645 [TBL] [Abstract][Full Text] [Related]
51. Ex vivo evaluation of pidotimod activity in patients with chronic obstructive pulmonary disease. Benetti GP; Illeni MT; Passera A; Bombelli G; Lavecchia G; Uslenghi C Arzneimittelforschung; 1994 Dec; 44(12A):1503-5. PubMed ID: 7857352 [TBL] [Abstract][Full Text] [Related]
52. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity. Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902 [TBL] [Abstract][Full Text] [Related]
53. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. Tremble LF; O'Brien MA; Soden DM; Forde PF Cancer Lett; 2019 Feb; 442():475-482. PubMed ID: 30472183 [TBL] [Abstract][Full Text] [Related]
54. Synthesis and preliminary pharmacological evaluation of pidotimod, its enantiomer, diastereomers and carboxamido derivatives. Magni A; Signorelli G; Bocchiola G Arzneimittelforschung; 1994 Dec; 44(12A):1402-4. PubMed ID: 7857331 [TBL] [Abstract][Full Text] [Related]
55. Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma. Sun F; Cui L; Li T; Chen S; Song J; Li D J Recept Signal Transduct Res; 2019 Jun; 39(3):208-214. PubMed ID: 31441696 [No Abstract] [Full Text] [Related]
56. Effects of pidotimod on the immune and the neuroendocrine system in the aging rat. Chiarenza A; Iurato MP; Barbera N; Lempereur L; Cantarella G; Scapagnini U; Scapagnini G; Bernardini R Arzneimittelforschung; 1994 Dec; 44(12A):1437-40. PubMed ID: 7857338 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils. Capsoni F; Minonzio F; Ongari AM; Girardello R; Zanussi C Pharmacol Res; 1992 Sep; 26 Suppl 2():172-3. PubMed ID: 1409296 [No Abstract] [Full Text] [Related]
58. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Motta G; De Campora E; De Vita C; Esposito S; Galletti C; Incutti V; Mallardi V; Motta S; Pucci V; Salonna F Arzneimittelforschung; 1994 Dec; 44(12A):1521-4. PubMed ID: 7857356 [TBL] [Abstract][Full Text] [Related]
59. The immunostimulatory effects and pro-apoptotic activity of rhCNB against Lewis lung cancer is mediated by Toll-like receptor 4. Yang J; Zhang H; Zhu Z; Gao Y; Xiang B; Wei Q Cancer Med; 2019 Aug; 8(9):4441-4453. PubMed ID: 31218844 [TBL] [Abstract][Full Text] [Related]
60. Bamodu OA; Kuo KT; Wang CH; Huang WC; Wu ATH; Tsai JT; Lee KY; Yeh CT; Wang LS Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]